NCT02185794 - Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

June 13, 2014

Primary Completion Date

December 22, 2014

Study Completion Date

September 28, 2015

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

Voxilaprevir

Voxilaprevir tablets administered orally once daily

DRUG

Placebo to match voxilaprevir

Placebo to match voxilaprevir tablets administered orally once daily

DRUG

SOF/VEL

400 mg/100 mg FDC tablet administered orally once daily

Trial Locations (11)

Costa Mesa

DeLand

Orlando

Kansas City

St Louis

Berlin

Marlton

Philadelphia

Knoxville

San Antonio

San Juan